Apr 27, 2014
ZonegranA (Zonisamide) Monotherapy Now Available in Russia for Adults With Newly Diagnosed Epilepsy
Zonisamide is a welcome new addition to our armamentarium in Epilepsy is one of the most common neurological conditions in the world. Around 3 out of every 1,000 people in live with the condition, 82% of which have partial epilepsy. The successful treatment of partial onset seizures remains a significant challenge and up to 30% of patients ... (more)
Mon Apr 21, 2014
ZonegranA (Zonisamide) Well Tolerated in Long-term Treatment of Children with Partial Epilepsy
ZonegranA is well tolerated and efficacious when used as an adjunctive treatment for partial epilepsy, with or without secondary generalisation, in children aged between 6-17 years for at least one year, according to the results of a new study published today in Epilepsia.
Sat Mar 15, 2014
Apac NSCLC and Epilepsy Therapeutics Market 2019 Forecasts
ReportsnReports.com offers "Epilepsy Therapeutics in Asia Pacific Markets to 2019 - Treatment Options Enhanced As Novel Next Generation AEDs Show Improved Safety and Tolerability" and "NSCLC Therapeutics in Asia-Pacific Markets to 2019 - Personalized Therapies Focus on Untapped Segment of Squamous Cell Carcinoma to Expand Treatment Pool" research ... (more)
Sun Mar 09, 2014
ZonegranA (Zonisamide) Approved for Use in Children and Adolescents...
ZonegranA has been approved by the Scottish Medicines Consortium for the treatment of partial epilepsy in adolescents and children aged six years and above in as adjunctive therapy for the treatment of partial seizures, with or without secondary generalisation, in adults, zonisamide is a second generation anti-epileptic drug with multiple ... (more)
Tue Feb 18, 2014
Epilepsy Treatment ZonegranA (Zonisamide) Receives Reimbursement in...
These issues, which are frequently manifested in an attention deficit disorder, withdrawal, anxiety or depression, have a negative impact on both the child and their family. as monotherapy in adults and the widened indication for its use as adjunctive therapy in children over the age of six and beyond is welcome and will provide a new treatment ... (more)